New Biomarker and Comorbidity Insights in NMOSD and MOGAD
Professor Nasrin Asgari shared updates at ECTRIMS 2024 on Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). He highlighting a potential new CNS protein biomarker, MFAP4, which may aid in predicting relapses. Additionally, studies on comorbidities show that over 50% of patients have at least one comorbidity, and 30% have multimorbidity, complicating treatment and worsening outcomes. Routine screening for these conditions is suggested to improve diagnosis and patient care.
